

GAVI'S SUPPORT FOR EMERGENCY VACCINE STOCKPILES

BOARD MEETING

Wilson Mok

7-8 December 2016, Abidjan, Côte d'Ivoire



Reach every child

www.gavi.org


OVERVIEW OF CURRENT ENGAGEMENT (1)



Yellow fever



Meningitis



Cholera

Gavi financial support:

- Vaccine costs
- Operational costs
- PEF funding (stockpile management and disease focal points)

OVERVIEW OF CURRENT ENGAGEMENT (2)

Approach

- International Coordinating Group (ICG) manages each stockpile; decisions on country requests
- Gavi funding disbursed to WHO, UNICEF
- WHO: Secretariat to ICG

Stockpile use: since 2006 ...

- 30 countries accessed stockpiles, 27 Gavi-supported
- 113 approved requests
- 72 million doses
- ~US\$ 90 million disbursed

THREE AREAS FOR ENHANCEMENT

**Strategic
design**

**Effective
implementation**

Accountability

STRATEGIC DESIGN

Lessons learned

- Piecemeal investments, not systematic
- Time-limited funding, not integrated within disease strategy
- Lacking processes when unforeseen needs arise
- Policies unclear or inconsistent

Proposed principles

Stockpile investments integral part of comprehensive disease strategy

Non-Gavi-supported countries access vaccine with reimbursement post-hoc

All Gavi-supported countries access vaccine and operational support up to \$0.65/targeted person

EFFECTIVE IMPLEMENTATION

Lessons learned

- Comparative advantage of Alliance partners not fully harnessed
- Single year forecasts, lacking structured approach
- Multiple procurement channels
- Limited country capacity

Proposed principles

Multi-year forecasts via collaborative, Alliance-wide effort

Single procurement agency, with agreed exceptions

Strengthening country capacity through existing funding approaches

ACCOUNTABILITY

Lessons learned

- Insufficient transparency on ICG dose allocation decisions
- Limited information impairs coordination, communication
- Performance indicators not clearly defined
- Inconsistent country post-campaign evaluation


Proposed principles

Transparent decision criteria; Gavi Secretariat observes decision process and participates on broader strategic issues

Real-time sharing of information

Reporting provides visibility to outcomes and lessons for mitigating future outbreaks

FINANCIAL IMPLICATIONS

- Investments no longer time-bound
 - Meningitis beyond 2017
 - Cholera beyond 2018 for emergency use of stockpile
 - Operational cost support for yellow fever and meningitis set at up to \$0.65 / targeted person
- 
- **Meningitis:** \$2M for 2017; \$47M for 2018-2020
 - **Cholera:** \$39M for 2019-2020
 - **Yellow fever:** increased operational support included separately in paper on update of comprehensive YF strategy

RECOMMENDATION

The Gavi Alliance Programme and Policy Committee recommended to the Gavi Alliance Board that it:

- a) **Approve** the principles set out in Figure 1 of Doc 13 for Gavi's support for emergency stockpiles of Gavi-supported vaccines as an integral part of integrated disease control strategies, as amended by discussions at the PPC, overriding previous Board decisions on Gavi's support for emergency stockpiles; and
- b) **Note** that additional funding associated with the adoption of the principles for the period 2017-2020 amount to approximately US\$86 million for meningitis and cholera.

Thank you



www.gavi.org